Literature DB >> 1933778

Stimulatory effects of growth hormone on rat bladder carcinogenesis.

H Akaza1, K Matsuki, H Matsushima, K Koiso, Y Aso.   

Abstract

The authors investigated the influences of recombinant human growth hormone (rh-GH) on rat urinary bladder carcinogenesis induced with N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN). Rats belonging to the control group (Group I, n = 19) were given 0.05% BBN in drinking water for 9 weeks, and the bladder was excised on the 22nd week after the initiation of BBN administration and inspected. All animals developed visible tumors in the bladder. The mean number of tumors per bladder was 11.26 +/- 5.21, and the mean total volume of tumors per bladder was 126.1 +/- 212.7 microliters. In all but one of the experimental groups (Group V) and in the control group, all animals developed visible tumors in the bladder. When 0.5 units of rh-GH was injected subcutaneously once a week from the week 1 through the week 6 (Group II; n = 20), the mean number of tumors and mean total volume of the tumors were 12.15 +/- 6.59 and 206.6 +/- 318.0 microliters, respectively. When the administration period of rh-GH was changed to between week 7 through the week 12 (Group III; n = 19), the mean number of tumors and mean total volume of the tumors were 16.95 +/- 7.07 and 204.5 +/- 317.7 microliters, respectively. When rh-GH was administered from the week 13 through the week 18 (Group IV; n = 19), the respective values were 16.79 +/- 10.75 and 213.4 +/- 274.6 microliters. In Group V (n = 19), which received only rh-GH from week 1 through the week 6, no tumors were detected. There were statistically significant differences in the mean tumor numbers between Groups I and III, Groups I and IV, and Groups II and III. The mean volume of individual tumor was the greatest in Group II, although the differences were not statistically significant in comparison with the other groups. Histologically, all tumors were transitional cell carcinoma in every group. There were no statistically significant differences in distributions of tumor stage and tumor grade between any groups. These findings suggest that rh-GH enhances the promotion of carcinogenesis of chemically induced rat urinary bladder cancer. It will be necessary to elucidate whether this effect of rh-GH is expressed by the somatostatin hypothesis of GH action, its direct action, or some other mechanisms.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933778     DOI: 10.1002/1097-0142(19911201)68:11<2418::aid-cncr2820681115>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Effects of short-term application of low-dose growth hormone on trace element metabolism and blood glucose in surgical patients.

Authors:  Kun Qian; Zhi Wan; Lang-Song Hao; Ming-Ming Zhang; Yong Zhou; Xiao-Ting Wu
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

2.  Short-term application of low-dose growth hormone in surgical patients: effects on nitrogen balance and blood glucose.

Authors:  Ming-Ming Zhang; Xiao-Ting Wu; Yong Zhou; Kun Qian; Ya-Min Zheng
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

3.  Growth hormone, alone and in combination with insulin, increases whole body and skeletal muscle protein kinetics in cancer patients after surgery.

Authors:  R S Berman; L E Harrison; D B Pearlstone; M Burt; M F Brennan
Journal:  Ann Surg       Date:  1999-01       Impact factor: 12.969

4.  In vitro effects of recombinant human growth hormone on growth of human gastric cancer cell line BGC823 cells.

Authors:  Jia-Yong Chen; Dao-Ming Liang; Ping Gan; Yi Zhang; Jie Lin
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

5.  Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients.

Authors:  R F Wolf; D B Pearlstone; E Newman; M J Heslin; A Gonenne; M E Burt; M F Brennan
Journal:  Ann Surg       Date:  1992-09       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.